Who are TMC435's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Riv, Triple therapy with ritonavir, abacavir/lamivudine + darunavir/ritonavir, continue the PI/r-containing HAART., lopinavir/ritonavir (LPV/r), LEXIVA (GW433908).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tmc435.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

TMC435 — Competitive Intelligence Brief

TMC435 (TMC435) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: protease inhibitor. Area: Infectious Diseases.

phase 3 protease inhibitor HIV-1 protease Infectious Diseases Small molecule Live · refreshed every 30 min

Target snapshot

TMC435 (TMC435) — Tibotec Pharmaceuticals, Ireland. TMC435 is a protease inhibitor used to treat HIV-1 infection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
TMC435 TARGET	TMC435	Tibotec Pharmaceuticals, Ireland	phase 3	protease inhibitor	HIV-1 protease
Riv	riv	Pfizer	marketed	Protease Inhibitors	HIV-1 protease
Triple therapy with ritonavir	Triple therapy with ritonavir	Sociedad Andaluza de Enfermedades Infecciosas	marketed	HIV protease inhibitor	HIV-1 protease
abacavir/lamivudine + darunavir/ritonavir	abacavir/lamivudine + darunavir/ritonavir	University of Modena and Reggio Emilia	phase 3	NRTI + PI	HIV-1 reverse transcriptase, HIV-1 protease
continue the PI/r-containing HAART.	continue the PI/r-containing HAART.	ASST Fatebenefratelli Sacco	phase 3	Protease inhibitor	HIV-1 protease
lopinavir/ritonavir (LPV/r)	lopinavir/ritonavir (LPV/r)	French National Agency for Research on AIDS and Viral Hepatitis	phase 3	Protease inhibitor	HIV-1 protease
LEXIVA (GW433908)	LEXIVA (GW433908)	ViiV Healthcare	phase 3	HIV protease inhibitor	HIV-1 protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (protease inhibitor class)

Tibotec Pharmaceuticals, Ireland · 3 drugs in this class
AbbVie · 1 drug in this class
AbbVie (prior sponsor, Abbott) · 1 drug in this class
R-Pharm · 1 drug in this class
Tanabe Pharma Corporation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TMC435 — Competitive Intelligence Brief. https://druglandscape.com/ci/tmc435. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab